La terapia más eficaz y segura

para un climaterio feliz

BENEFICIOS
Apego al tratamiento 3, Archer. DF, et al. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause. 2012;19(6):622-9 8 Travassos de Figueiredo Alves et al. Comparison of gel and patch estradiol replacement in Brazil, a tropical country. Maturitas. 2000;36(1):69-74.
No mancha 9 Naunton M et al. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause. 2006;13(3):517-27
Comodidad 9 Naunton M et al. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause. 2006;13(3):517-27
No deja residuos 1 Archer DF. Estradiol Gel: a new option in hormone replacement therapy. OBG Management. 2004:46-66.
Rápida absorcion 10 Castelo-Branco et al. Clinical efficacy of estradiol transdermal system in the treatment of hot fashes in postmenopausal women. Res Rep Transderm Drug Deliv. 2014;3:1–8.
Niveles de fármacos estables 3, Castelo-Branco et al. Clinical efficacy of estradiol transdermal system in the treatment of hot fashes in postmenopausal women. Res Rep Transderm Drug Deliv. 2014;3:1–8. 8, Travassos de Figueiredo Alves et al. Comparison of gel and patch estradiol replacement in Brazil, a tropical country. Maturitas. 2000;36(1):69-74. 10 Castelo-Branco et al. Clinical efficacy of estradiol transdermal system in the treatment of hot fashes in postmenopausal women. Res Rep Transderm Drug Deliv. 2014;3:1–8.
Individualización de la dosis 9 Naunton M et al. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause. 2006;13(3):517-27
No causa irritación 8, Travassos de Figueiredo Alves et al. Comparison of gel and patch estradiol replacement in Brazil, a tropical country. Maturitas. 2000;36(1):69-74. 9 Naunton M et al. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause. 2006;13(3):517-27
Evita el efecto del primer paso hepático 11 Bergendal A, et al. Riesgo de tromboembolia venosa asociada con el uso local y sistémico de terapia hormonal en mujeres peri y postmenopáusicas y en relación con el tipo y la vía de administración. Menopause. 2016;23(6):593-9.
No incrementa el riesgo de TEV 2 Modena MG, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
No modifica el perfil de lípidos 2 Modena MG, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
Disminuye triglicéridos 2 Modena MG, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
No incrementa la proteína C reactiva 2 Modena MG, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
No modifica o disminuye la presión arterial 12, Cannoletta M, et al. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health. 2014; 11 (6): 745 – 57. 13 Ichikawa J, et al. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006; 19 (7):744 – 9.